Amnion epithelial cells - A novel therapy for ischemic stroke?

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Stroke is a leading cause of death and disability and new therapies are desperately needed. Given the complex nature of ischemic brain injury, it has been postulated that cell-based therapies may be useful. However, cell resources, invasive extraction procedures, immunological rejection, tumorigenesis and ethical challenges make it unlikely that many stem cell types could serve as a practical source for therapy. By contrast, these issues do not pertain to human amnion epithelial cells (hAECs), which are placenta-derived stem cells. We recently assessed the effects of systemically delivered hAECs on stroke outcome using four animal models of stroke. We demonstrated that when injected intravenously after ischemia onset, hAECs migrate preferentially to the spleen and injured brain to limit apoptosis and inflammation, and attenuate early brain infiltration of immune cells, progression of infarction and systemic immunosuppression and to ultimately ameliorate functional deficits. When administration of hAECs is delayed by 1-3 days post-stroke, long-term functional recovery can still be enhanced in young and aged mice of either sex. Moreover, our proof-of-principle findings suggest that hAECs are effective at limiting post-stroke infarct development in non-human primates. Overall, the results suggest that hAECs could be a viable clinical stroke therapy.

Original languageEnglish
Pages (from-to)1346-1349
Number of pages4
JournalNeural Regeneration Research
Volume13
Issue number8
DOIs
Publication statusPublished - 1 Aug 2018

Keywords

  • Brain repair
  • Cerebral infarction
  • Human amnion epithelial cells
  • Immunosuppression
  • Inflammation
  • Ischemic stroke
  • Mouse
  • Non-human primate
  • Stem cells

Cite this

@article{c82fa9585c844dea9882a29427fc9898,
title = "Amnion epithelial cells - A novel therapy for ischemic stroke?",
abstract = "Stroke is a leading cause of death and disability and new therapies are desperately needed. Given the complex nature of ischemic brain injury, it has been postulated that cell-based therapies may be useful. However, cell resources, invasive extraction procedures, immunological rejection, tumorigenesis and ethical challenges make it unlikely that many stem cell types could serve as a practical source for therapy. By contrast, these issues do not pertain to human amnion epithelial cells (hAECs), which are placenta-derived stem cells. We recently assessed the effects of systemically delivered hAECs on stroke outcome using four animal models of stroke. We demonstrated that when injected intravenously after ischemia onset, hAECs migrate preferentially to the spleen and injured brain to limit apoptosis and inflammation, and attenuate early brain infiltration of immune cells, progression of infarction and systemic immunosuppression and to ultimately ameliorate functional deficits. When administration of hAECs is delayed by 1-3 days post-stroke, long-term functional recovery can still be enhanced in young and aged mice of either sex. Moreover, our proof-of-principle findings suggest that hAECs are effective at limiting post-stroke infarct development in non-human primates. Overall, the results suggest that hAECs could be a viable clinical stroke therapy.",
keywords = "Brain repair, Cerebral infarction, Human amnion epithelial cells, Immunosuppression, Inflammation, Ischemic stroke, Mouse, Non-human primate, Stem cells",
author = "Evans, {Megan A.} and Broughton, {Brad R.S.} and Drummond, {Grant R.} and Henry Ma and Phan, {Thanh G.} and Wallace, {Euan M.} and Rebecca Lim and Sobey, {Christopher G.}",
year = "2018",
month = "8",
day = "1",
doi = "10.4103/1673-5374.235223",
language = "English",
volume = "13",
pages = "1346--1349",
journal = "Neural Regeneration Research",
issn = "1673-5374",
publisher = "Medknow Publications",
number = "8",

}

Amnion epithelial cells - A novel therapy for ischemic stroke? / Evans, Megan A.; Broughton, Brad R.S.; Drummond, Grant R.; Ma, Henry; Phan, Thanh G.; Wallace, Euan M.; Lim, Rebecca ; Sobey, Christopher G.

In: Neural Regeneration Research, Vol. 13, No. 8, 01.08.2018, p. 1346-1349.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Amnion epithelial cells - A novel therapy for ischemic stroke?

AU - Evans, Megan A.

AU - Broughton, Brad R.S.

AU - Drummond, Grant R.

AU - Ma, Henry

AU - Phan, Thanh G.

AU - Wallace, Euan M.

AU - Lim, Rebecca

AU - Sobey, Christopher G.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Stroke is a leading cause of death and disability and new therapies are desperately needed. Given the complex nature of ischemic brain injury, it has been postulated that cell-based therapies may be useful. However, cell resources, invasive extraction procedures, immunological rejection, tumorigenesis and ethical challenges make it unlikely that many stem cell types could serve as a practical source for therapy. By contrast, these issues do not pertain to human amnion epithelial cells (hAECs), which are placenta-derived stem cells. We recently assessed the effects of systemically delivered hAECs on stroke outcome using four animal models of stroke. We demonstrated that when injected intravenously after ischemia onset, hAECs migrate preferentially to the spleen and injured brain to limit apoptosis and inflammation, and attenuate early brain infiltration of immune cells, progression of infarction and systemic immunosuppression and to ultimately ameliorate functional deficits. When administration of hAECs is delayed by 1-3 days post-stroke, long-term functional recovery can still be enhanced in young and aged mice of either sex. Moreover, our proof-of-principle findings suggest that hAECs are effective at limiting post-stroke infarct development in non-human primates. Overall, the results suggest that hAECs could be a viable clinical stroke therapy.

AB - Stroke is a leading cause of death and disability and new therapies are desperately needed. Given the complex nature of ischemic brain injury, it has been postulated that cell-based therapies may be useful. However, cell resources, invasive extraction procedures, immunological rejection, tumorigenesis and ethical challenges make it unlikely that many stem cell types could serve as a practical source for therapy. By contrast, these issues do not pertain to human amnion epithelial cells (hAECs), which are placenta-derived stem cells. We recently assessed the effects of systemically delivered hAECs on stroke outcome using four animal models of stroke. We demonstrated that when injected intravenously after ischemia onset, hAECs migrate preferentially to the spleen and injured brain to limit apoptosis and inflammation, and attenuate early brain infiltration of immune cells, progression of infarction and systemic immunosuppression and to ultimately ameliorate functional deficits. When administration of hAECs is delayed by 1-3 days post-stroke, long-term functional recovery can still be enhanced in young and aged mice of either sex. Moreover, our proof-of-principle findings suggest that hAECs are effective at limiting post-stroke infarct development in non-human primates. Overall, the results suggest that hAECs could be a viable clinical stroke therapy.

KW - Brain repair

KW - Cerebral infarction

KW - Human amnion epithelial cells

KW - Immunosuppression

KW - Inflammation

KW - Ischemic stroke

KW - Mouse

KW - Non-human primate

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=85051791882&partnerID=8YFLogxK

U2 - 10.4103/1673-5374.235223

DO - 10.4103/1673-5374.235223

M3 - Review Article

VL - 13

SP - 1346

EP - 1349

JO - Neural Regeneration Research

JF - Neural Regeneration Research

SN - 1673-5374

IS - 8

ER -